Tudor Investment Corp
IRLA

Tudor Investment Corp’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Tudor Investment Corp’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16
Closed -$294K – 2890
2021
Q3 		$294K Buy
+16
New +$254K ﹤0.01% 2054

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tudor Investment Corp's IRLA Position: Q4 2021 in Review

Tudor Investment Corp sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2021, closing a stake of 16 shares — an estimated $294K sold.

Tudor Investment Corp first reported a position in IRLA in Q3 2021 and held it in 1 quarter. The position peaked at $294K in Q3 2021. 98 funds tracked by Wall St. Rank hold IRLA as of Q4 2021.

  • Tudor Investment Corp reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Tudor Investment Corp sold 16 IRulya Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $294K.
  • Tudor Investment Corp first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Tudor Investment Corp's IRulya Therapeutics Inc. Common Stock position peaked at $294K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2021.

Based on Tudor Investment Corp's 13F filing for Q4 2021, filed 14 Feb 2022.